Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Astellas Pharma Inc.
  6. News
  7. Summary
    4503   JP3942400007


SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Astellas Pharma : Real-World Evidence Studies Provide Further Insight into Negative Impacts of Vasomotor Symptoms Associated with Menopause

09/29/2020 | 09:22am EDT

TOKYO - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., 'Astellas') today announced findings from two Real-World Evidence (RWE) studies and a qualitative sleep survey that underscore the prevalence of vasomotor symptoms (VMS) associated with menopause and the disruptive impact of these symptoms on sleep.

These data will be presented during two pre-recorded oral presentations and one poster session at The North American Menopause Society (NAMS) 2020 Virtual Annual Meeting, available online starting September 28, 2020.

Vasomotor symptoms (VMS) comprising of hot flashes and night sweats - are the most common symptoms associated with menopause1,2 and are often reported as the most bothersome.3

'These studies better characterize the burden of vasomotor symptoms associated with menopause and underscore the negative impacts on quality of life for women, particularly as it relates to sleep,' said Judith Nelissen, Ph.D., Vice President, Head of Health Economics and Outcomes Research (HEOR), Medical Affairs, Astellas. 'At Astellas, we remain committed to creating and delivering value for women in need of new treatment options to address vasomotor symptoms.'

In a retrospective analysis of the racially and culturally diverse midlife women participating in the Study of Women's Health Across the Nation (SWAN) database, high VMS frequency was associated with greater odds of sleep problems (i.e., difficulty falling asleep, waking early and sleep interruption) and worse sleep quality. After controlling for VMS frequency, other comorbidities, and a range of covariates, women with migraines or arthritis were also at higher risk of worse sleep. Three comorbidities were found to amplify or attenuate the association between VMS frequency and of sleep quality: diabetes, hypertension, and migraines. These findings warrant further investigation, as greater understanding may help healthcare providers better tailor treatment plans for their patients.

Results from a global prospective online survey showed 34 percent of postmenopausal women in the U.S. (mean age was 57 years) experience moderate-to-severe VMS, and 61 percent of those women experience associated sleep disturbances. Hot flashes and night sweats were shown to be among the top five most bothersome symptoms based on the Menopause-specific Quality of Life Questionnaire (MENQOL). Additionally, 47 percent of U.S. respondents had contacted their healthcare provider within the last year to discuss hot flashes and night sweats. Results also showed an economic burden of menopause-related symptoms in terms of healthcare resource utilization and out-of-pocket costs and support the need for developing newer treatments for menopause-related symptoms.

About Vasomotor Symptoms (VMS)

Globally, approximately 57 percent of women 40 to 64 years of age have reported the occurrence of hot flashes (also known as hot flushes) and sweating.4 VMS can have a considerable effect on women's comfort and sleep and can lead to anxiety, irritability, loss of productivity and depression.5 Hot flashes are also the most common symptom for women transitioning through menopause.6

About Astellas

Astellas Pharma Inc. is a pharmaceutical company conducting business in more than 70 countries around the world. We are promoting the Focus Area Approach that is designed to identify opportunities for the continuous creation of new drugs to address diseases with high unmet medical needs by focusing on Biology and Modality. Furthermore, we are also looking beyond our foundational Rx focus to create Rx+ healthcare solutions that combine our expertise and knowledge with cutting-edge technology in different fields of external partners. Through these efforts, Astellas stands on the forefront of healthcare change to turn innovative science into value for patients.

Cautionary Notes

In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties.

Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.


Anna Otten

Tel: +1 (224) 205-6651

Email: anna.otten@astellas.com

(C) 2020 Electronic News Publishing, source ENP Newswire

06/17ASTELLAS PHARMA  : Notice Regarding Impairment Loss Following the Termination of..
06/16ASTELLAS PHARMA  : Transfers Five Legacy Products in Europe, Russia, CIS and Asi..
06/09ASTELLAS PHARMA  : New Research Reflects Astellas' Commitment to Acute Myeloid L..
06/08Heavyweights pull Nikkei lower, Topix gains on drugmakers' boost
06/07Nikkei falls as market heavyweights offset gains in drugmakers
06/02ASTELLAS PHARMA  : Reviewing capabilities for sustainable growth - Astellas Will..
06/02PRESS RELEASE : MorphoSys to Acquire Constellation -2-
05/31Japanese shares end lower on profit-booking, drugmakers limit losses
05/30Japanese shares retreat from 3-week high; drugmakers limit losses
05/26Japanese shares fall on profit-taking, pandemic worries
More news
Sales 2021 1 259 B 11 459 M 11 459 M
Net income 2021 176 B 1 606 M 1 606 M
Net cash 2021 522 B 4 748 M 4 748 M
P/E ratio 2021 20,1x
Yield 2021 2,16%
Capitalization 3 609 B 32 733 M 32 853 M
EV / Sales 2021 2,45x
EV / Sales 2022 2,40x
Nbr of Employees 15 883
Free-Float 99,0%
Duration : Period :
Astellas Pharma Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTELLAS PHARMA INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 13
Average target price 2 455,38 JPY
Last Close Price 1 943,00 JPY
Spread / Highest target 85,3%
Spread / Average Target 26,4%
Spread / Lowest Target -15,1%
EPS Revisions
Managers and Directors
Kenji Yasukawa President, CEO & Representative Director
Yoshihiko Hatanaka Chairman
Yoshitsugu Shitaka Chief Scientific Officer
Fumiaki Sakurai Head-Business Administration & Compliance
Mamoru Sekiyama Independent Outside Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON2.92%426 557
ROCHE HOLDING AG12.70%325 803
PFIZER, INC.5.43%217 246
NOVARTIS AG2.47%208 642
ABBVIE INC.5.57%199 795